Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hypertonic saline nasal wash is a concentrated sodium chloride solution (specifically 1.8% NaCl in the Stanford University protocol) used for the management of chronic rhinosinusitis (CRS). Unlike standard isotonic saline (0.9%), the hypertonic formulation creates an osmotic pressure gradient that draws excess fluid out of the edematous nasal mucosa, thereby reducing swelling and improving nasal airflow. Additionally, it acts to decrease the viscosity of nasal secretions, facilitating the mechanical clearance of thickened mucus, allergens, and inflammatory mediators by the ciliary system. The solution is typically buffered to a physiological pH to minimize irritation and optimize patient tolerability during large-volume irrigation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hypertonic saline nasal wash.